Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE + HAIC vs HAIC for Large HCC
NCT05263219Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2022
- Primary completion
- Feb 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirarubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Overall Survival at 4 years. Started Feb 2022; status: recruiting.
02
Drugs
pirarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05263219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263219.